Show Me the Outcomes!
|
|
- Hope Baldwin
- 5 years ago
- Views:
Transcription
1 Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds October 3 rd, MFMER slide-1
2 80 Annual Prevalence of Oral Anticoagulant Use Prevalence (%) Warfarin Alalwan et al. Am J Health-Syst Pharm. 2017;74: MFMER slide-2
3 80 Annual Prevalence of Oral Anticoagulant Use Prevalence (%) Warfarin All DOACs DOACs: direct oral anticoagulants Alalwan et al. Am J Health-Syst Pharm. 2017;74: MFMER slide-3
4 80 Annual Prevalence of Oral Anticoagulant Use Prevalence (%) Warfarin All DOACs Dabigatran Rivaroxaban Apixaban DOACs: direct oral anticoagulants Alalwan et al. Am J Health-Syst Pharm. 2017;74: MFMER slide-4
5 Objectives Review landmark trials for the use of apixaban, dabigatran, and rivaroxaban in nonvalvular atrial fibrillation Discuss post-approval data for bleeding risk with oral anticoagulants Outline general recommendations for oral anticoagulation based on post-approval safety data 2017 MFMER slide-5
6 Dabigatran RE-LY Evaluation of stroke or SE Mean CHADS 2 = 2.1 CHADS 2 3 = 32% Prior stroke, SE, or TIA = 20.1% Warfarin time in therapeutic range = 64% Lower rates of stroke and SE with 150 mg Lower bleeding rates with 110 mg Similar bleeding rates with 150 mg SE: systemic embolism Connolly et al. N Engl J Med. 2009;361: TIA: transient ischemic attack Patel et al. N Engl J Med. 2011;365: Granger et al. N Engl J Med. 2011;365: MFMER slide-6
7 Dabigatran RE-LY Evaluation of stroke or SE Mean CHADS 2 = 2.1 CHADS 2 3 = 32% Prior stroke, SE, or TIA = 20.1% Warfarin time in therapeutic range = 64% Lower rates of stroke and SE with 150 mg Lower bleeding rates with 110 mg Similar bleeding rates with 150 mg Rivaroxaban ROCKET AF Evaluation of stroke or SE Mean CHADS 2 = 3.5 CHADS 2 3 = 87% Prior stroke, SE, or TIA = 54.9% Warfarin time in therapeutic range = 55% Noninferior to warfarin No significant difference in major bleeding risk SE: systemic embolism Connolly et al. N Engl J Med. 2009;361: TIA: transient ischemic attack Patel et al. N Engl J Med. 2011;365: Granger et al. N Engl J Med. 2011;365: MFMER slide-7
8 Dabigatran Rivaroxaban Apixaban RE-LY ROCKET AF ARISTOTLE Evaluation of stroke or SE Evaluation of stroke or SE Evaluation of stroke or SE Mean CHADS 2 = 2.1 CHADS 2 3 = 32% Prior stroke, SE, or TIA = 20.1% Warfarin time in therapeutic range = 64% Lower rates of stroke and SE with 150 mg Lower bleeding rates with 110 mg Similar bleeding rates with 150 mg Mean CHADS 2 = 3.5 CHADS 2 3 = 87% Prior stroke, SE, or TIA = 54.9% Warfarin time in therapeutic range = 55% Noninferior to warfarin No significant difference in major bleeding risk Mean CHADS 2 = 2.1 CHADS 2 3 = 30% Prior stroke, SE, or TIA = 19.2% Warfarin time in therapeutic range = 62.2% Superior to warfarin Less bleeding Lower mortality SE: systemic embolism Connolly et al. N Engl J Med. 2009;361: TIA: transient ischemic attack Patel et al. N Engl J Med. 2011;365: Granger et al. N Engl J Med. 2011;365: MFMER slide-8
9 AVERROES 5 Events per year (%) p < Apixaban Aspirin 0 Stroke or SE Connolly et al. N Engl J Med. 2011;364: MFMER slide-9
10 AVERROES 5 Events per year (%) p < p = Apixaban Aspirin 0 Stroke or SE Major Bleeding Connolly et al. N Engl J Med. 2011;364: MFMER slide-10
11 Landmark Trial Conclusions Clinical efficacy of DOACs similar to warfarin Apixaban and dabigatran (150 mg) superior to warfarin Apixaban and dabigatran (110 mg) associated with significantly lower rates of major bleeding All others non-inferior to warfarin Limitations: Poor adherence/high discontinuation rates Numerous exclusion criteria Applicability to general population 2017 MFMER slide-11
12 Patient Case AB is a 68-year-old female who presents with new-onset nonvalvular atrial fibrillation for 72 hours. She will be started on oral anticoagulation. Past medical history: hypertension, diabetes mellitus, history of stroke CHADS 2 score = MFMER slide-12
13 Question #1 Based on the landmark trials, which drug would you select for this patient? Apixaban Dabigatran Rivaroxaban Warfarin 2017 MFMER slide-13
14 Question #2 In your opinion, which oral anticoagulant has the highest bleeding risk in post-approval data? Apixaban Dabigatran Rivaroxaban Warfarin 2017 MFMER slide-14
15 Warfarin vs DOAC Methods Large U.S. administrative claims database Time Period July 1 st, 2006 to June 30 th, 2016 Population Outcomes 107,373 new adult users ( 18 years) of oral anticoagulants for nonvalvular atrial fibrillation Warfarin, apixaban, dabigatran, or rivaroxaban Inpatient admission for one of the following: Stroke (efficacy) Major bleeding (safety) Noseworthy et al. Int J Cardiol. 2017;245: MFMER slide-15
16 60 50 Baseline Characteristics: CHA 2 DS 2 -VASc * Patients (%) * Warfarin Apixaban Dabigatran Rivaroxaban CHA 2 DS 2 -VASc Noseworthy et al. Int J Cardiol. 2017;245: MFMER slide-16
17 40 Baseline Characteristics: HAS-BLED Patients (%) * * Warfarin Apixaban Dabigatran Rivaroxaban 5 0 0, HAS-BLED Noseworthy et al. Int J Cardiol. 2017;245: MFMER slide-17
18 Oral Anticoagulant Efficacy and Safety Ischemic stroke or SE Major bleeding Event incidence (%) Warfarin Apixaban Dabigatran Rivaroxaban Noseworthy et al. Int J Cardiol. 2017;245: MFMER slide-18
19 6 Oral Anticoagulant Efficacy Warfarin Apixaban Dabigatran Rivaroxaban 5.5 Ischemic stroke or SE (%) CHA 2 DS 2 -VASc Noseworthy et al. Int J Cardiol. 2017;245: MFMER slide-19
20 25 Oral Anticoagulant Safety Warfarin Apixaban Dabigatran Rivaroxaban Major bleeding (%) , HAS-BLED Noseworthy et al. Int J Cardiol. 2017;245: MFMER slide-20
21 Real-World Comparison: Warfarin vs DOAC Similar efficacy among agents Major bleeding risk: Highest with warfarin Lowest with apixaban Increased stroke or systemic embolism risk with higher CHA 2 DS 2 -VASc score Increased major bleeding risk with higher HAS-BLED score 2017 MFMER slide-21
22 DOAC vs DOAC Methods Large U.S. administrative claims database Time Period October 1 st, 2010 to February 28 th, 2015 Population Outcomes Adult users ( 18 years) of apixaban, dabigatran, or rivaroxaban for nonvalvular atrial fibrillation 3 propensity-score-matched cohorts: Rivaroxaban vs dabigatran (n = 31,574) Apixaban vs dabigatran (n = 13,084) Apixaban vs rivaroxaban (n = 13,130) Median CHA 2 DS 2 -VASc = 4 Median HAS-BLED = 2 Stroke and systemic embolism (efficacy) Major bleeding (safety) Noseworthy et al. CHEST. 2016;150: MFMER slide-22
23 Stroke or Systemic Embolism Event rate per 100 person-years Rivaroxaban vs Dabigatran Favor Rivaroxaban Apixaban vs Dabigatran Favor Dabigatran Hazard ratio p value Apixaban vs Rivaroxaban Favor Apixaban Favor Apixaban Favor Dabigatran Favor Rivaroxaban Noseworthy et al. CHEST. 2016;150: MFMER slide-23
24 Major Bleeding Event rate per 100 person-years Rivaroxaban vs Dabigatran Favor Rivaroxaban Apixaban vs Dabigatran Favor Dabigatran Hazard ratio p value 1.30 < <0.001 Apixaban vs Rivaroxaban Favor Apixaban Favor Apixaban Favor Dabigatran Favor Rivaroxaban 0.39 <0.001 Noseworthy et al. CHEST. 2016;150: MFMER slide-24
25 Intracranial Bleeding Event rate per 100 person-years Rivaroxaban vs Dabigatran Favor Rivaroxaban Apixaban vs Dabigatran Favor Dabigatran Hazard ratio p value Apixaban vs Rivaroxaban Favor Apixaban Favor Apixaban Favor Dabigatran Favor Rivaroxaban Noseworthy et al. CHEST. 2016;150: MFMER slide-25
26 DOAC vs DOAC: Gastrointestinal Bleed Methods Large U.S. administrative claims database Time Period October 1 st, 2010 to February 28 th, 2015 Population Adult users ( 18 years) of apixaban, dabigatran, or rivaroxaban for nonvalvular atrial fibrillation 3 propensity-score-matched cohorts: Rivaroxaban vs dabigatran (n = 31,574) Apixaban vs dabigatran (n = 13,084) Apixaban vs rivaroxaban (n = 13,130) Median CHA 2 DS 2 -VASc = 4 Median HAS-BLED = 2 Outcome Gastrointestinal bleed Abraham et al. Gastroenterology. 2017;152; MFMER slide-26
27 Gastrointestinal Bleeding Events Hazard Ratio Apixaban vs dabigatran (n = 13,084) Overall 0.39 Age years 0.38 Age years 0.25 Age 75 years 0.45 p <0.05 Abraham et al. Gastroenterology. 2017;152; MFMER slide-27
28 Gastrointestinal Bleeding Events Hazard Ratio Apixaban vs dabigatran (n = 13,084) Apixaban vs rivaroxaban (n = 13,130) Overall Age years Age years Age 75 years p <0.05 Abraham et al. Gastroenterology. 2017;152; MFMER slide-28
29 Gastrointestinal Bleeding Events Hazard Ratio Apixaban vs dabigatran (n = 13,084) Apixaban vs rivaroxaban (n = 13,130) Rivaroxaban vs dabigatran (n = 31,574) Overall Age years Age years Age 75 years p <0.05 Abraham et al. Gastroenterology. 2017;152; MFMER slide-29
30 Real-World Comparison: DOAC vs DOAC Similar efficacy Major, intracranial, and gastrointestinal bleeding risk: Rivaroxaban > Dabigatran > Apixaban Limitations: Reliance on pharmacy claims data and billing codes Potential residual confounding 2017 MFMER slide-30
31 1 st Apixaban Lowest major bleeding risk Lowest gastrointestinal bleeding risk Chronic kidney disease 2017 MFMER slide-31
32 1 st Apixaban Lowest major bleeding risk Lowest gastrointestinal bleeding risk 2 nd Dabigatran Lower major bleeding risk than rivaroxaban and warfarin Reversal agent Chronic kidney disease 2017 MFMER slide-32
33 3 rd Rivaroxaban Highest major bleeding risk among DOACs Highest gastrointestinal bleeding risk among DOACs Compliance issues 2017 MFMER slide-33
34 3 rd Rivaroxaban Highest major bleeding risk among DOACs Highest gastrointestinal bleeding risk among DOACs Compliance issues Warfarin Chronic kidney disease Compliance issues Reversal agents Valves 2017 MFMER slide-34
35 Question #3 AB develops a GI bleed on rivaroxaban therapy and requires a change in oral anticoagulant therapy. Which alternative agent would you select for her? Apixaban Dabigatran Warfarin 2017 MFMER slide-35
36 Questions & Discussion 2017 MFMER slide-36
37 Acquisition Costs Drug Mayo Clinic Acquisition Cost Warfarin $0.04 Apixaban $4.54 Dabigatran $5.20 Rivaroxaban $ MFMER slide-37
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationΧάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. ΓΕΝΝΗΜΑΤΑΣ»
Η ισορροπία ασφάλειας και αποτελεσματικότητας: Η συνέπεια στα αποτελέσματα των τυχαιοποιημένων κλινικών μελετών και των δεδομένων κλινικής πρακτικής της Απιξαμπάνης Χάρης Κοσσυβάκης Επιμελητής A Καρδιολογικό
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationTSHP 2014 Annual Seminar 1
Debate: Versus the Rest of the World for Stroke Prevention in Non-valvular Atrial Fibrillation Matthew Wanat, PharmD, BCPS Clinical Assistant Professor University of Houston College of Pharmacy Clinical
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationPrimary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC
Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion Greg Francisco, MD, FACC DISCLOSURES None to declare Estimated 33.5million have AF worldwide (6-7million in
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationState of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data
State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data Massimo Grimaldi Ospedale F. Miulli Acquaviva delle Fonti - Bari Disclosure Biosense
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationNOACs in AF. Dr Fiona Stewart. Auckland Heart Group and Auckland DHB
NOACs in AF Dr Fiona Stewart Auckland Heart Group and Auckland DHB NOACS for AF True/False All patients should have a CHA 2 DS 2 VASc risk assessment on diagnosis of AF NOACS are more effective than warfarin
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club Dr. Lianjie Xiong Dr. Xiong is a PGY2 cardiology pharmacy resident at Vanderbilt University Medical Center in Nashville, TN. She went to Nova Southeastern University and
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationDirect Oral Anticoagulant Use in Valvular Atrial Fibrillation
Direct Oral Anticoagulant Use in Valvular Atrial Fibrillation September 14, 2018 Nina Maguire, PharmD PGY1 Pharmacy Resident Seton Healthcare Family Christina.maguire@ascension.org ASCENSION TEXAS Direct
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationLeft Atrial Appendage Closure 4 questions Who? When? How? Results?
Left Atrial Appendage Closure 4 questions Who? When? How? Results? David R. Holmes, Jr., M.D. Mayo Clinic, Rochester ACC New York CVS New York, NY December 2017 2012 MFMER slide-1 Presenter Disclosure
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationPrepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution
Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationAF review. Petr Polasek
AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationFred Kusumoto Professor of Medicine
Fred Kusumoto Professor of Medicine Faculty photo will be placed here Kusumoto.Fred@mayo.edu 2015 MFMER 3543652-1 Atrial Fibrillation Presentation Subtitle Here Mayo School of Continuous Professional Development
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationCondition Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C Left ventricular dysfunction I50.1; I50.9 E11 1; E11 9
Comparative effectiveness and safety of non-vitamin K antagonists oral anticoagulants (OACs) and warfarin in daily clinical practice: A propensity weighted nationwide cohort study. Supplementary material
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationLeft Atrial Appendage Closure: The Rationale
Left Atrial Appendage Closure: The Rationale JOHN D. HUMMEL, MD DIRECTOR OF CLINCAL ELECTROPHYSIOLOGY RESEARCH PROFESSOR OF CLINICAL INTERNAL MEDICINE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER 1 Disclosures
More informationThrombosis and Thromboembolsim October Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy
Thrombosis and Thromboembolsim October 2012 Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy Christian T. Ruff, MD, MPH TIMI Study Group Brigham and Women
More informationStudy period Total sample size (% women) 899 (37.7%) Warfarin Aspirin
Table S2 Sex- specific differences in oral anticoagulant prescription for stroke prevention in AF Total sample size (% women) Anticoagulant(s) studied Gage (2000) 1 Missouri, USA Discharged during 597
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationAF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China
AF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China Case report 64-year-old Chinese man with history of hypertension,
More informationControversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk
Controversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk Boyoung Joung, MD, PhD Professor, Division of Cardiology Director of Electrophysiology Laboratory Severance Cardiovascular
More informationEdoxaban in Atrial Fibrillation
Edoxaban in Atrial Fibrillation Glenn Gormley, MD, PhD Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Co., Ltd Nov. 4, 2014 Tuesday Background Based on the results of ENGAGE AF-TIMI 48,
More informationFINAL CDEC RECOMMENDATION
FINAL CDEC RECOMMENDATION APIXABAN (Eliquis Bristol-Myers Squibb Canada and Pfizer Canada Inc.) New Indication: Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation Recommendation:
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationTroponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy. Ziad Hijazi, MD
Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy Ziad Hijazi, MD Uppsala Clinical Research Center (UCR) Uppsala University, Sweden Co-authors:
More informationAtrial Fibrillation. Alan Bell, MD, CCFP. Staff Physician, Humber River Regional Hospital. University of Toronto
Pearls in Thrombosis 1 Atrial Fibrillation Alan Bell, MD, CCFP Staff Physician, Humber River Regional Hospital Assistant tprofessor, Department tof Family and Community Mdii Medicine University of Toronto
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More informationUpdates in Atrial Fibrillation
Updates in Atrial Fibrillation Michael Curley, MD Cardiac Electrophysiologist Wheaton Franciscan Medical Group #1 Most common heart rhythm disturbance 1 in 4 Americans over 40 will be diagnosed 3,500,000
More informationAbstract. Introduction. imedpub Journals Doson Chua* Research Article. Cardiovascular Investigations: Open Access
Research Article imedpub Journals www.imedpub.com Cardiovascular Investigations: Open Access Vol. 2 No.1: 1 Use of Non-vitamin K Antagonist Oral Anticoagulants (NOAC) for Stroke Prevention in Patients
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationTrends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation,
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 Junya Zhu, PhD Department of Health Policy and Management January 23, 2018 Acknowledgments Co-Authors G.
More informationIdentifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
More informationAtrial Fibrillation in the Elderly: Causes, Symptoms, and Treatment
Atrial Fibrillation in the Elderly: Causes, Symptoms, and Treatment Asa Oxner, MD Assistant Professor of Medicine Division of General Internal Medicine University of South Florida Co-Investigator: Geriatric
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationTechnology appraisal guidance Published: 27 February 2013 nice.org.uk/guidance/ta275
Apixaban for preventing enting stroke and systemic embolism in people with nonvalvular atrial fibrillation Technology appraisal guidance Published: 27 February 2013 nice.org.uk/guidance/ta275 NICE 2018.
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationAnti-Coagulation in a Healthcare System that Cannot Afford Direct Oral Anticoagulants for Everyone
Anti-Coagulation in a Healthcare System that Cannot Afford Direct Oral Anticoagulants for Everyone Doreen Tan Cardiology Specialist Pharmacist 2017.04.08 Navigation Map Atrial Fibrillation What s the fuss?
More informationControversies in Risk Stratification
Controversies in Risk Stratification Things are not as simple as they seem Banff 2017 2015 MFMER 3494750-5 Relative importance Triggers vs Substrate in Pathophysiology of AF AF burden Paroxysmal? Persistent?
More informationEpidemiology current status: heart and brain
Epidemiology current status: heart and brain Veikko Salomaa, MD, PhD Research Professor 22.5.2012 Heart and brain/ Veikko Salomaa 1 Veikko Salomaa, MD, PhD Research Professor National Institute for Health
More informationUse of Anticoagulants in Geriatrics: Current Evidence and Special Considerations
Use of Anticoagulants in Geriatrics: Current Evidence and Special Considerations Aryn You, PharmD Assistant Professor, Pharmacy Practice The Daniel K. Inouye College of Pharmacy Aida Wen, MD Associate
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationDaniela Poli 12 Novembre 2016
Daniela Poli 12 Novembre 2016 Prevalence of AF in relation to age and sex
More informationObjectives. Falling Down on Warfarin Therapy. CHADS 2 Score. CHADS 2 & CHA 2 DS 2 -VASc Score. HAS-BLED Score 04/08/2014. Real World Application
Falling Down on Warfarin Therapy David Andrew Jacob, PharmD Pharmacy Resident 2013-2014 Dayton VA Medical Center Dayton, Ohio Objectives Describe CHADS 2 score and the decision to anticoagulate patients
More informationRecanalization Therapy & Secondary Prophylaxis in the Elderly
Recanalization Therapy & Secondary Prophylaxis in the Elderly 21 st Annual Meeting of the Swiss Stroke Society Lausanne,11.01.2018 PD Dr. G. M. De Marchis, MD MSc Neurology & Stroke Center University Hospital
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationLeft Atrial Appendage Occlusion in the Era of Novel Anticoagulants
Left Atrial Appendage Occlusion in the Era of Novel Anticoagulants Saibal Kar, MD, FACC, FSCAI Professor of Medicine Director of Interventional Cardiac Research Heart Institute, Cedars-Sinai Medical Center,
More informationDraft Agreed by Cardiovascular Working Party 25 Jan Adoption by CHMP for release for consultation 17 Feb 2011
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 London, 25 January 2011 EMA/CHMP/68875/2011 Committee for Medicinal Products for Human Use (CHMP) Concept paper on the need for a guideline on clinical investigation
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationAnticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
More informationΣεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή
Σεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή Δξελίξειρ ζηην ανηιπηκηική αγωγή ζε αζθενείρ με κολπική μαπμαπςγή Ξςδώναρ Σωηήπιορ Μονάδα Δμθπαγμάηων και
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationMohammad Zubaid, MB, ChB, FRCPC, FACC
Management and one year outcome of atrial fibrillation in Middle Eastern cohort enrolled in the observational Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Mohammad Zubaid, MB, ChB, FRCPC, FACC
More informationקוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן
קוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן INTRODUCTION The prevalence of atrial fibrillation (AF) is approximately 1.5 2% of the general population The arrhythmia is associated: with
More informationAntithrombotics in the elderly. Robert Gabor Kiss FESC FACC Budapest
Antithrombotics in the elderly Robert Gabor Kiss FESC FACC Budapest The patient in the elderly You are sitting in Your office prescribing drugs and observing outcome The black box from prescription to
More informationDirect oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation
J Thromb Thrombolysis (2016) 42:573 578 DOI 10.1007/s19-016-1410-z Direct oral anticoagulant use and the incidence of in the very elderly with atrial fibrillation Fatima Khan 1,2 Hans Huang 2 Yvonne H.
More informationUtilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention
Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationTrick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT?
Trick or Treat 2: A New Era of Stroke Prevention in AF? WATCHMAN and LARIAT? Disclosure SentreHeart, Inc Consultant Equity holder A cardiac disease that kills by producing emboli The most severe consequence
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationSUPPLEMENTAL MATERIALS
SUPPLEMENTAL MATERIALS Table S1: Variables included in the propensity-score matching Table S1.1: Components of the CHA 2DS 2Vasc score Table S2: Crude event rates in the compared AF patient cohorts Table
More information